Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Total Valuation
Revolution Medicines has a market cap or net worth of $6.78B. The enterprise value is $6.10B.
Market Cap$6.78B
Enterprise Value$6.10B
Share Statistics
Revolution Medicines has 185.91M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding185.91M
Owned by Insiders6.45%
Owned by Instutions0.05%
Financial Efficiency
Revolution Medicines’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -28.68%.
Return on Equity (ROE)-26.49%
Return on Assets (ROA)-23.46%
Return on Invested Capital (ROIC)-28.68%
Return on Capital Employed (ROCE)-28.80%
Revenue Per Employee$0
Profits Per Employee-$1,123,769.663
Employee Count534
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Revolution Medicines is -12.23. Revolution Medicines’s PEG ratio is 1.69.
PE Ratio-12.23
PS Ratio0.00
PB Ratio3.24
Price to Fair Value3.24
Price to FCF-12.92
Price to Operating Cash Flow-13.16
PEG Ratio1.69
Income Statement
In the last 12 months, Revolution Medicines had revenue of $0.00 and earned -$600.09M in profits. Earnings per share was -$3.61.
Revenue$0.00
Gross Profit-$130.80M
Operating Income-$689.52M
Pretax Income-$600.85M
Net Income-$600.09M
EBITDA-682.92M
Earnings Per Share (EPS)-3.61
Cash Flow
In the last 12 months, operating cash flow was -$557.44M and capital expenditures -$10.31M, giving a free cash flow of -$567.74M billion.
Operating Cash Flow-$557.44M
Free Cash Flow-$567.74M
Free Cash Flow per Share-$3.05
Dividends & Yields
Revolution Medicines pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-7.74%
Earnings Yield-8.18%
Stock Price Statistics
Beta1.35
52-Week Price Change0.61%
50-Day Moving Average38.69
200-Day Moving Average44.33
Relative Strength Index (RSI)50.77
Average Volume (3m)1.76M
Important Dates
Revolution Medicines upcoming earnings date is May 12, 2025, Before Open.
Last Earnings DateFeb 26, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Revolution Medicines as a current ratio of 14.20, with Debt / Equity ratio of 0.06
Current Ratio14.20
Quick Ratio14.20
Debt to Market Cap0.02
Net Debt to EBITDA0.59
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Revolution Medicines has paid -$753.00K in taxes.
Income Tax-$753.00K
Effective Tax Rate-0.13%
Enterprise Valuation
Revolution Medicines EV to EBITDA ratio is -10.05, with an EV/FCF ratio of -12.21.
EV to Sales0.00
EV to EBITDA-10.05
EV to Free Cash Flow-12.21
EV to Operating Cash Flow-12.43
Balance Sheet
Revolution Medicines has $2.29B in cash and marketable securities with $135.84M in debt, giving a net cash position of -$2.15B billion.
Cash & Marketable Securities$2.29B
Total Debt$135.84M
Net Cash-$2.15B
Net Cash Per Share-$11.58
Tangible Book Value Per Share$13.08
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Revolution Medicines is $68.30, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$68.30
Price Target Upside87.28%
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast-100.00%
EPS Growth Forecast5.49%